The FDA is offering priority review support for selected psilocybin and methylone programs, while allowing one noribogaine study to proceed and preparing final trial guidance.
The FDA has announced steps to support the development of psychedelic-related treatments for serious mental illness, following an April 18 executive order focused on speeding medical treatment development in this area.
The FDA is issuing Commissioner’s National Priority Vouchers to selected development programs, allowing an early-stage study of noribogaine hydrochloride to move forward and preparing final guidance for companies developing serotonin-2A agonists and related products.
The voucher is meant to give selected applications more direct FDA communication and a shorter one- to two-month review window after a New Drug Application (NDA) is filed.
The priority vouchers apply to three programs involving psilocybin or methylone for depression and post-traumatic stress disorder (PTSD). The FDA did not name the companies in its announcement. However, Compass Pathways and Transcend Therapeutics later said they received vouchers.
The FDA also allowed an early-stage clinical study of noribogaine hydrochloride to proceed under an Investigational New Drug (IND) submission. The sponsor, DemeRx NB, is studying noribogaine as a potential treatment for alcohol use disorder.
Noribogaine is related to ibogaine, a psychedelic compound being studied for substance use disorders. According to the FDA, this is the first time the agency has allowed a US clinical study of an ibogaine derivative.
The clearance allows DemeRx NB to begin testing the drug in a closely monitored clinical setting in the US. The FDA also noted that allowing the study to proceed does not mean the drug has been approved or found to be safe or effective.
The agency also plans to release final guidance that is expected to cover trial design, data collection, patient monitoring and the evidence needed to support adequate and well-controlled clinical studies.
The final guidance will build on the FDA’s first draft guidance on psychedelic drug trials, which covered products such as psilocybin, LSD and MDMA. That earlier draft also addressed practical challenges in this type of research, including how to account for psychoactive effects during blinded trials and how patients should be monitored during treatment sessions.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
The executive order also directs agencies to prioritize certain psychedelic drug candidates with Breakthrough Therapy designation, support legal access pathways where applicable and encourage evidence generation through collaboration among HHS, the FDA, the Department of Veterans Affairs and the private sector.
Psychedelic drug therapy work is already moving through the clinic. Compass said the FDA granted its request for rolling NDA submission and review for COMP360, based on Phase III data in treatment-resistant depression. COMP360 generated positive data from two large, well-controlled Phase III trials, with data across more than 1,000 participants living with treatment-resistant depression, according to the press release.
Transcend’s TSND-201 is now enrolling patients in a Phase III clinical trial in the US. TSND-201 is an investigational rapid-acting neuroplastogen, and Transcend said it does not act at 5-HT2A receptors, meaning it is not being developed as a hallucinogenic treatment.
The FDA announcement also follows a separate December 2025 executive order focused on medical marijuana and cannabidiol research. In April 2026, the Justice Department and DEA shifted certain FDA-approved and state-licensed medical marijuana products into a less restrictive federal category, which could make it easier to study those products while keeping federal controls in place.
FAQs
Why is FDA guidance important for psychedelic-related trials?
FDA guidance helps companies understand what evidence the agency expects before it reviews a treatment for possible approval. For psychedelic-related therapies, this can include expectations around study design, data collection and patient monitoring.
What is the difference between FDA review support and FDA approval?
Review support can help a company communicate with the FDA or move through review faster. Approval means the FDA has determined that a product’s benefits outweigh its risks for a specific use.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN